+357 96 030922
info@marketpublishers.com

Global Vaccine Adjuvants Market - 2025 -2033

https://marketpublishers.com/r/G0848AFC1466EN.html
Date: October 2025
Pages: 180
Price: US$ 4,350.00 (Single User License)
ID: G0848AFC1466EN

Abstracts

Vaccine Adjuvants Market Size & Industry Outlook

The global vaccine adjuvants market size reached US$ 703.15 Million in 2024 from US$ 661.09 Million in 2023 and is expected to reach US$ 1,280.35 Million by 2033, growing at a CAGR of 6.9% during the forecast period 2025-2033. The market is evolving as a critical enabler of next-generation vaccines, driven by the need to enhance immunogenicity in subunit, recombinant, and emerging mRNA platforms. Traditional mineral salts such as alum remain widely used in pediatric and adult prophylactic vaccines, while advanced systems like MF59, AS03, and AS01 have gained prominence in influenza, shingles, and malaria programs.

Recent approvals, such as CpG 1018 in hepatitis B vaccines, highlight the growing role of TLR agonists in commercial products. Demand is also fueled by oncology and therapeutic vaccine research, where potent adjuvant systems like QS-21 and liposome-based formulations are being tested. North America currently leads adoption due to established vaccine pipelines and regulatory approvals, but emerging markets like APAC are gaining traction through local production and government immunization drives.

Key Market Trends & Insights

Key trends in the vaccine adjuvants market reflect a shift from conventional alum-based systems toward more sophisticated adjuvant platforms that can enhance targeted immune responses. Oil-in-water emulsions such as MF59 and AS03 are increasingly used in seasonal and pandemic influenza vaccines, while liposome-based systems like AS01, used in GSK’s Shingrix and malaria vaccine Mosquirix, set benchmarks for efficacy in older adults and complex pathogens. TLR agonists, exemplified by Dynavax’s CpG 1018 in hepatitis B

+357 96 030922
info@marketpublishers.com

vaccines, demonstrate the rising acceptance of nucleic acid-based adjuvants in licensed products.

The integration of adjuvants with mRNA and protein subunit platforms, particularly highlighted during COVID-19 vaccine development. Oncology and therapeutic vaccine pipelines are also accelerating demand for potent adjuvants like QS-21 and novel nanoparticles.

North America dominates the vaccine adjuvants market with the largest revenue share of 44.02% in 2024.

The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 6.8% over the forecast period.

Based on application, the infectious diseases segment led the market with the largest revenue share of 49.87% in 2024.

The major market players in the vaccine adjuvants market are GSK, Dynavax Technologies, Novavax, SPI Pharma, Agenus Inc., CSL, InvivoGen, Brenntag Nicaragua, S.A., and OZ Biosciences, among others

Market Size & Forecast

2024 Market Size: US$ 703.15 Million

2033 Projected Market Size: US$ 1,280.35 Million

CAGR (2025–2033): 6.9%

North America: Largest market in 2024

Asia Pacific: Fastest-growing market

Market Dynamics

Drivers-The rising threat of emerging infectious diseases and pandemics is significantly driving the vaccine adjuvants market growth

+357 96 030922
info@marketpublishers.com

The rising threat of emerging infectious diseases and pandemics is increasingly shaping the vaccine adjuvants market, as global health systems seek technologies that can both accelerate vaccine development and extend protection in high-risk populations. Unlike traditional live or inactivated vaccines, many modern platforms such as protein subunit, recombinant, and mRNA vaccines often produce weaker immune responses and therefore depend on adjuvants to boost efficacy. This became especially evident during the 2009 H1N1 influenza pandemic, when AS03-adjuvanted vaccines like Pandemrix and Arepanrix enabled dose-sparing, allowing more than 90 million doses to be distributed worldwide despite limited antigen supply.

The COVID-19 crisis further underscored the value of adjuvants, with Novavax's Matrix-M-adjuvanted vaccine earning emergency approvals in multiple countries and demonstrating strong immunogenicity comparable to mRNA platforms. The same R21/MATRIX-M is also central to the R21 malaria vaccine, which recently achieved 77% efficacy (according to the NIH), setting a benchmark for next-generation prophylactic vaccines. Beyond commercial successes, public health organizations like CEPI and BARDA have prioritized adjuvants in their preparedness strategies, funding platforms that can be rapidly adapted to new pathogens.

Additionally, the increasing frequency of zoonotic spillovers such as SARS-CoV-2, avian influenza strains, and Ebola outbreaks keeps the spotlight on technologies that can shorten vaccine timelines. In this context, adjuvants offer clear advantages, they enhance antigen efficiency, provide cross-protective immunity, and extend the durability of protection, all of which are crucial in outbreak settings. Industry leaders like GSK, Novavax, and Dynavax are at the forefront. Taken together, these factors show that the constant threat of pandemics is no longer just a temporary driver but a structural catalyst for sustained investment, innovation, and growth in the vaccine adjuvants market.

Restraints-Safety concerns and reactogenicity risks are hampering the growth of the vaccine adjuvants market

Safety concerns and reactogenicity risks remain among the most significant restraints hampering the growth of the vaccine adjuvants market, as stakeholders struggle to balance the clear benefits of enhanced immunogenicity with the potential for higher rates of side effects. While adjuvants like alum have been used safely for decades, reports of rare but controversial conditions such as macrophagic myofasciitis have fueled lingering skepticism in some populations.

+357 96 030922
info@marketpublishers.com

More advanced systems, including AS01 (used in GSK’s Shingrix) and AS03 (used in pandemic influenza vaccines like Pandemrix), have set new efficacy benchmarks but also demonstrated increased rates of local and systemic reactions compared with traditional alum-based formulations. Grade 3 systemic reactions such as fatigue, myalgia, and fever were also significantly more common in adjuvanted arms, with relative risks sometimes up to three times higher than controls, though serious adverse events and deaths were extremely rare (

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

5. VACCINE ADJUVANTS MARKET, BY PRODUCT TYPE

6. VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

+357 96 030922
info@marketpublishers.com

7. VACCINE ADJUVANTS MARKET, BY APPLICATION

8. VACCINE ADJUVANTS MARKET, BY END-USER

9. BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Vaccine Adjuvants Market - 2025 -2033
Product link: https://marketpublishers.com/r/G0848AFC1466EN.html
Price: US$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G0848AFC1466EN.html